Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonidegib - Novartis

Drug Profile

Sonidegib - Novartis

Alternative Names: Erismodegib; Erismodegib-phosphate; LDE-225; NVP-LDE-225; Odomzo; Sonidegib-phosphate

Latest Information Update: 27 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; University of Alabama at Birmingham
  • Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
  • Phase I/II Myelofibrosis; Pancreatic cancer
  • Phase I Breast cancer
  • No development reported Chronic myeloid leukaemia; Graft-versus-host disease; Liver cancer; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Basal cell nevus syndrome

Most Recent Events

  • 10 Dec 2018 Genoptix has been acquired by NeoGenomics
  • 19 Oct 2018 Final efficacy and adverse events data from the phase II BOLT trial in Basal cell carcinoma presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 01 Aug 2018 Novartis completes a phase I trial in Myelodysplastic syndromes (Combination therapy) in France (PO) (NCT02323139)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top